The expression of cd74-regulated inflammatory markers in stage iv melanoma: Risk of cns metastasis and patient survival

Dai Ogata, Jason Roszik, Junna Oba, Sun Hee Kim, Roland L. Bassett, Lauren E. Haydu, Keiji Tanese, Elizabeth A. Grimm, Suhendan Ekmekcioglu

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Innate inflammatory features have been found in melanoma tumors from patients at all stages, and molecular analysis has identified definitive inflammatory proteins expressed by tumors cells in patients who presents the worst prognosis. We have previously observed weakened outcomes in patients with constitutive expression of inducible nitric oxide synthase (iNOS), macrophage migration inhibitory factor (MIF) and improved outcomes with CD74 expression in stage III melanoma. In our current study, we tested our hypothesis on CD74-regulated inflammatory markers’ expression in stage IV melanoma tumors whether the signature is associated with survival outcome and/or risk of developing CNS metastasis. We retrospectively identified 315 patients with stage IV melanoma. In a tissue microarray (TMA), we examined the expression of cells with CD74, its receptor MIF, and downstream inflammatory markers iNOS, nitrotyrosine (NT), cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase-1 (mPGES1). We analyzed the association of those inflammatory markers with overall survival time (OS) and time to CNS metastasis using Kaplan–Meier survival analyses. Our data validates CD74 as a useful prognostic tumor cell protein marker associated with favorable OS as in stage III melanomas, while the tumor NT expression strongly predicts an increased risk of developing CNS metastasis (p = 0.0008) in those patients.

Original languageEnglish
Article number3754
Pages (from-to)1-13
Number of pages13
Issue number12
Publication statusPublished - 2020 Dec


  • CD74
  • CNS metastasis
  • Melanoma
  • Nitrotyrosine
  • Prognosis
  • Stage IV

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The expression of cd74-regulated inflammatory markers in stage iv melanoma: Risk of cns metastasis and patient survival'. Together they form a unique fingerprint.

Cite this